Evidence library

Do GLP-1s weaken your bones?

Losing weight on a GLP-1 can lower bone density, a downside most coverage skips. Here is what the evidence shows about how much, and the one thing shown to protect bone while the drug takes weight off.

How to read these grades

Evidence strength

  • Strong evidence (does / reduces / improves)
  • Moderate evidence (probably / likely)
  • Early / weak evidence (may / might)

Tested in GLP-1 users?

  • Tested in GLP-1 users
  • Not tested in GLP-1 users
  • Trial underway

Weight loss on a GLP-1 can lower bone density and speed up bone turnover

Moderate evidence Tested in GLP-1 users

Losing weight on a GLP-1 probably reduces bone density at the hip and spine and raises markers of bone breakdown. This has been measured in people on the drug, though at diabetes-level doses of specific agents, not the higher obesity doses.

What it rests on

  • Hansen 2024 1

    A trial gave adults at higher fracture risk semaglutide at the 1.0 mg diabetes dose for about a year. Bone-turnover markers rose and bone density fell roughly 2% at the spine and 2.6% at the hip as people lost about 9% of their weight.

    Semaglutide 1.0 mg, higher-fracture-risk adults

  • Jensen 2024 2

    A randomized trial compared exercise alone, the GLP-1 liraglutide alone, and the two combined after weight loss. The drug-alone group lost bone at the hip and spine, while the group that added exercise kept bone density level with placebo despite losing the most weight.

    Liraglutide 3.0 mg

What would change this grade

Bone density is a stand-in for fracture risk, not fracture risk itself. No trial has yet shown these drugs change how often bones actually break.

Exercise is the lever that protects bone while the drug takes weight off

Moderate evidence Tested in GLP-1 users

Adding structured exercise, especially resistance and weight-bearing training, probably protects the bone that weight loss would otherwise cost you. The one direct trial used liraglutide, so read it as promising rather than settled.

What it rests on

  • Jensen 2024 2

    A randomized trial compared exercise alone, the GLP-1 liraglutide alone, and the two combined after weight loss. The drug-alone group lost bone at the hip and spine, while the group that added exercise kept bone density level with placebo despite losing the most weight.

    Liraglutide 3.0 mg

  • Mozaffarian 2025 advisory 3

    A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

    Four-society expert consensus

Calcium and vitamin D are raw material for bone, not a builder, and D alone does not prevent fractures

Moderate evidence Not tested in GLP-1 users

Vitamin D on its own makes little or no difference to fractures. Taken with calcium it is linked to modestly fewer fractures, but these are the raw materials bone needs, not something that builds bone. The evidence is from older populations, not GLP-1 users.

What it rests on

  • Yao 2019 4

    A large pooled analysis of fracture trials. Vitamin D on its own did not reduce fractures; vitamin D taken with calcium was linked to about 16% fewer hip fractures, an effect driven mostly by one trial in older or institutionalized people.

    Older/institutionalized, not GLP-1

  • Mozaffarian 2025 advisory 3

    A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

    Four-society expert consensus

How fast you lose weight may matter to your bones, not just how much

Early / weak evidence Not tested in GLP-1 users

More rapid and larger weight loss may go with more bone loss, so a slower, steadier pace might preserve more bone. This is a reasonable idea drawn from expert consensus, not something proven in people on GLP-1s, and the primary study behind it is still being sourced.

What it rests on

  • Mozaffarian 2025 advisory 3

    A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

    Four-society expert consensus

Sources

  1. 1. Hansen MS, Wölfel EM, Jeromdesella S, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. eClinicalMedicine. 2024;72:102624. doi:10.1016/j.eclinm.2024.102624
  2. 2. Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment. JAMA Netw Open. 2024;7(6):e2416775. doi:10.1001/jamanetworkopen.2024.16775
  3. 3. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023
  4. 4. Yao P, Bennett D, Mafham M, et al. Vitamin D and Calcium for the Prevention of Fracture. JAMA Netw Open. 2019;2(12):e1917789. doi:10.1001/jamanetworkopen.2019.17789